share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K：重大事件
美股sec公告 ·  05/23 16:07
Moomoo AI 已提取核心信息
On May 20, 2024, Avalo Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company does not meet the Nasdaq Capital Market's continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The notice was issued following Avalo Therapeutics' report of negative $112.6 million in stockholders' equity for the quarter ended March 31, 2024. The company has been given 45 days, until July 5, 2024, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 days for the company to demonstrate compliance. Avalo Therapeutics' common stock will continue to trade on the Nasdaq under the symbol 'AVTX' during this period. The company is exploring options to regain compliance, but there is no guarantee that...Show More
On May 20, 2024, Avalo Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company does not meet the Nasdaq Capital Market's continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The notice was issued following Avalo Therapeutics' report of negative $112.6 million in stockholders' equity for the quarter ended March 31, 2024. The company has been given 45 days, until July 5, 2024, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 days for the company to demonstrate compliance. Avalo Therapeutics' common stock will continue to trade on the Nasdaq under the symbol 'AVTX' during this period. The company is exploring options to regain compliance, but there is no guarantee that the Nasdaq will accept its plan or that compliance will be achieved within any granted extension period. Failure to regain compliance could lead to a delisting determination, although the company would have the right to request a hearing before a Nasdaq Hearings Panel to present its compliance plan and request an additional extension.
2024年5月20日，Avalo Therapeutics, Inc.收到纳斯达克上市资格部门的通知，表明该公司不符合纳斯达克资本市场关于维持至少250万美元股东权益的持续上市要求。该通知是在Avalo Therapeutics报告截至2024年3月31日的季度股东权益为负1.126亿美元之后发布的。在2024年7月5日之前，该公司有45天的时间提交恢复合规的计划。如果该计划被接受，纳斯达克可能会给予公司长达180天的时间来证明其合规性。在此期间，Avalo Therapeutics的普通股将继续在纳斯达克上市，股票代码为 “AVTX”。该公司正在探索恢复合规性的备选方案，但无法保证纳斯达克会接受其计划，也无法保证在任何允许的延期内实现合规。未能恢复合规性可能会导致退市决定，尽管该公司有权要求纳斯达克听证会小组举行听证会，以提交其合规计划并要求进一步延期。
2024年5月20日，Avalo Therapeutics, Inc.收到纳斯达克上市资格部门的通知，表明该公司不符合纳斯达克资本市场关于维持至少250万美元股东权益的持续上市要求。该通知是在Avalo Therapeutics报告截至2024年3月31日的季度股东权益为负1.126亿美元之后发布的。在2024年7月5日之前，该公司有45天的时间提交恢复合规的计划。如果该计划被接受，纳斯达克可能会给予公司长达180天的时间来证明其合规性。在此期间，Avalo Therapeutics的普通股将继续在纳斯达克上市，股票代码为 “AVTX”。该公司正在探索恢复合规性的备选方案，但无法保证纳斯达克会接受其计划，也无法保证在任何允许的延期内实现合规。未能恢复合规性可能会导致退市决定，尽管该公司有权要求纳斯达克听证会小组举行听证会，以提交其合规计划并要求进一步延期。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息